替吉奥联合沙利度胺治疗老年晚期胃癌的临床研究  

Clinic Research of S-1 Combined with Thalidomide in the Treatment of elderly Patients with Advanced Gastric Cancer

作　　者：秦岭[1] 张章[1] 刘鹏英[1] 齐志峰[1] 孙玲玲[1] 江伟[1] 吴越菲[1] 周勤[1] 

机构地区：[1]安徽省芜湖市第二人民医院肿瘤科,241000

出　　处：《岭南急诊医学杂志》2013年第6期450-452,共3页Lingnan Journal of Emergency Medicine

摘　　要：目的:观察替吉奥联合沙利度胺方案治疗老年晚期胃癌的临床疗效。方法:将2008年1月至2012年12月我院收治的老年晚期胃癌患者43例随机分为替吉奥联合沙利度胺组(研究组)22例和替吉奥组(对照组)21例,比较两组疗效及不良反应。结果:研究组有效率40.9%虽高于对照组的28.6%,但无显著性差异(P>0.05);研究组的疾病控制率和生活质量总改善率均明显高于对照组(P均<0.05);研究组的中位生存期及1年生存率均优于对照组,但差异无统计学意义(P>0.05)。与对照组相比,研究组的恶心呕吐、厌食发生率低,便秘的发生率高,(P均<0.05)。结论:与单药替吉奥化疗相比,替吉奥联合沙利度胺能增加晚期胃癌患者的疾病控制率,改善患者的生活质量,且不良反应轻。Objective：To observe the clinic curative effects of S-1 capsules combined with Thalidomide in elderly patients with advanced gastric cancer. Methods：43 elderly patients with advanced gastric cancer were randomly divided into S-1 capsules combined with Thalidomide group （research group, n=22） and S-1 capsules group （control group, n=21） from Jan 2008 to Dec 2012. The clinic effects and adverse reactions were compared between the two groups. Results： The effective rate in research group （40.9%） was no significantly different than that in the control group （28.6%）, P 〉 0.05. The clinically profit rate and life quality in the research group were significantly higher than those in the control group （both P 〈 0.05）. The median survival and 1-year survival rate in the research group were no significantly better than those in the control group （both P 〉 0.05）.Compared with the control group, nausea vomiting and anorexia were less and constipation was more pronounced in the research group （all P 〈 0.05）. Conclusion：Compared with S-1 capsules regimen, thalidomide combined with S-1 capsules regimen obviously increase clinically profiting rate and improve life quality of the patients with advanced gastric cancer resulting in less toxicities.

关 键 词：晚期胃癌 沙利度胺 替吉奥胶囊 化疗 老年患者 

分 类 号：R735.2[医药卫生—肿瘤]